Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.

Period	Debt/Equity
2021-12-31	0.05
2022-12-31	0.14
2023-12-31	0.13
2024-12-31	0.20

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AURA	$6.75	+1.73%	0.24M
3
4
5

Aura Biosciences Inc. (AURA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Aura Biosciences Inc. Data in Excel

More AURA Financial Data